Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
16.69
+0.07 (0.42%)
Nov 20, 2026, 10:01 AM EST - Market open
Xeris Biopharma Holdings Revenue
Xeris Biopharma Holdings had revenue of $107.23M in the quarter ending September 30, 2026, with 44.16% growth. This brings the company's total for the last twelve months to $368.26M, up 38.37% year-over-year. In the year 2025, Xeris Biopharma Holdings had annual revenue of $291.85M with 43.72% growth. That makes Xeris Biopharma Holdings the 13,173rd largest company in the world by revenue and 2,481st in the United States.
Revenue (ttm)
$368.26M
Revenue Growth
+38.37%
P/S Ratio
8.25
Revenue / Employee
$846,572
Employees
435
Market Cap
3.05B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 291.85M | 88.78M | 43.72% |
| Dec 31, 2024 | 203.07M | 39.16M | 23.89% |
| Dec 31, 2023 | 163.91M | 53.67M | 48.68% |
| Dec 31, 2022 | 110.25M | 60.66M | 122.32% |
| Dec 31, 2021 | 49.59M | 29.16M | 142.67% |
| Dec 31, 2020 | 20.44M | 17.71M | 650.73% |
| Dec 31, 2019 | 2.72M | 299.00K | 12.34% |
| Dec 31, 2018 | 2.42M | 867.00K | 55.72% |
| Dec 31, 2017 | 1.56M | 481.00K | 44.74% |
| Dec 31, 2016 | 1.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 11.11B |
| Perrigo Company | 4.09B |
| Hims & Hers Health | 2.87B |
| Prestige Consumer Healthcare | 1.17B |
| Trulieve Cannabis | 1.08B |
| BioCryst Pharmaceuticals | 961.51M |
| Liquidia | 621.87M |
| HUTCHMED (China) | 549.12M |
XERS News
- 3 days ago - Xeris Biopharma Holdings Transcript: Jefferies Global Healthcare Conference - Transcripts
- 9 days ago - Xeris Biopharma price target raised to $18 from $14 at Barclays - TheFly
- 14 days ago - Xeris Biopharma price target raised to $18 from $12 at Craig-Hallum - TheFly
- 14 days ago - Xeris Biopharma price target raised to $21 from $18 at Oppenheimer - TheFly
- 14 days ago - Xeris Biopharma price target raised to $12 from $8 at Piper Sandler - TheFly
- 14 days ago - Xeris Biopharma price target raised to $18 from $10 at H.C. Wainwright - TheFly
- 15 days ago - Xeris Biopharma Holdings Earnings Call Transcript: Q3 2026 - Transcripts
- 15 days ago - Xeris Biopharma Holdings Earnings release: Q3 2026 - Filings